Stay updated with breaking news from Practice Guidelines. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The NCCN has updated their guidelines for soft tissue sarcoma to include the γ-secretase inhibitor nirogacestat as a systemic therapy option for patients with desmoid tumors, granting the agent a preferred, category 1 recommendation.
– Accelerating Innovation and Growth Strategy with Top-Line Data Readouts Expected in 2H 2024 and 2025 from Three Pivotal Phase 3 Studies Evaluating Selinexor in Multiple Myeloma, Endometrial...
Medical oncologist Lucio N. Gordan MD, president and managing physician of Florida Cancer Specialists & Research Institute, LLC, is lead author of the first real-world study comparing the two preferred regimens recommended for the primary treatment of non-transplant patients with newly-diagnosed multiple myeloma, published recently in Science Direct.
LONGUEUIL, Quebec, Jan. 04, 2024 -- Azimut Exploration Inc. is pleased to announce that it has filed on SEDAR+ an independent Technical Report prepared in accordance with National Instrument...
Azimut Exploration Inc. ("Azimut" or the "Company") is pleased to announce that it has filed on SEDAR+ an independent Technical Report (the "Report") prepared in accordance with National Instrument 43-101 for the Patwon Gold Zone on its 100% owned...